QuantLogix ← TMO scorecard
📅 TMO Earnings Preview
Thermo Fisher Scientific, Inc.
Next report (est.)
11/21/2026
Countdown
74 days
EPS growth YoY
+9.3%
Revenue growth YoY
+10.5%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
07/31/2026 ±3.1% -0.4% over-priced
05/01/2026 ±2.7% -2.0% over-priced
10/31/2025 ±2.1% +2.0% over-priced
08/01/2025 ±2.5% -1.0% over-priced
05/02/2025 ±2.7% +0.9% over-priced
11/01/2024 ±1.5% +2.1% under-priced
08/02/2024 ±2.1% -1.0% over-priced
05/03/2024 ±1.9% +0.2% over-priced
Across these reports, options implied an average ±2.3% move vs an actual average of 1.2% — the stock stayed inside the implied band 88% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $4.68 $12.0B $1.7B
Q1 FY2026 $4.43 $11.0B $1.7B
Q4 FY2025 $5.21 $12.2B $2.0B
Q3 FY2025 $4.27 $11.1B $1.6B
Analyst posture
Buy / Strong Buy
29
Hold
7
Sell
0
Stable: +0 net change 30d
Live 5-factor engine read: Strong Buy · 60/100 Full scorecard →
Get alerted before every TMO report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on TMO before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Thermo Fisher Scientific, Inc. (TMO) reports in 74 days, with the next report estimated for 11/21/2026. Across the last 8 reports, options priced an average ±2.3% earnings move while the stock actually moved 1.2% on average — the market has systematically over-priced TMO's earnings risk. Fundamentals into the print: EPS up 9.3% year-over-year, revenue up 10.5%. QuantLogix's live 5-factor engine currently reads TMO as a strong buy at 60/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →